stem cell transplantation in patients with acute myeloid leukemia (AML) Azacitidine augments expansion of regulatory T cells after allogeneic

[1]  A. Kiani,et al.  Minimal residual disease-directed preemptive treatment with azacitidine in patients with NPM1-mutant acute myeloid leukemia and molecular relapse , 2011, Haematologica.

[2]  B. Falini,et al.  Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. , 2011, Blood.

[3]  Krishna Komanduri,et al.  Maintenance therapy with low‐dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome , 2010, Cancer.

[4]  C. Craddock,et al.  CD8+ T-cell immunity against cancer-testis antigens develops following allogeneic stem cell transplantation and reveals a potential mechanism for the graft-versus-leukemia effect , 2010, Haematologica.

[5]  W. Shannon,et al.  In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia. , 2010, Blood.

[6]  J. Karbach,et al.  The DNA demethylating agent 5-aza-2'-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells. , 2010, Leukemia research.

[7]  P. Vyas,et al.  Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia. , 2010, Blood.

[8]  P. Vyas,et al.  Factors predicting long-term survival after T-cell depleted reduced intensity allogeneic stem cell transplantation for acute myeloid leukemia , 2010, Haematologica.

[9]  N. Kröger,et al.  5-Azacytidine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome who relapse after allo-SCT: a retrospective analysis , 2010, Bone Marrow Transplantation.

[10]  H. Dombret,et al.  Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  F. J. Gonzalez,et al.  Immunomodulatory effect of 5-azacytidine (5-azaC): potential role in the transplantation setting. , 2010, Blood.

[12]  H. Kantarjian,et al.  Low‐dose azacitidine after allogeneic stem cell transplantation for acute leukemia , 2009, Cancer.

[13]  K. Rezvani,et al.  Ex vivo characterization of polyclonal memory CD8+ T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia. , 2009, Blood.

[14]  Mario Roederer,et al.  High avidity myeloid leukemia-associated antigen-specific CD8+ T cells preferentially reside in the bone marrow. , 2009, Blood.

[15]  D. Levy,et al.  Epigenetic Regulation of Foxp3 Expression in Regulatory T Cells by DNA Methylation1 , 2009, The Journal of Immunology.

[16]  C. Huber,et al.  Rapid identification and sorting of viable virus-reactive CD4(+) and CD8(+) T cells based on antigen-triggered CD137 expression. , 2008, Journal of immunological methods.

[17]  Christoph Schmid,et al.  Matched unrelated or matched sibling donors result in comparable survival after allogeneic stem-cell transplantation in elderly patients with acute myeloid leukemia: a report from the cooperative German Transplant Study Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  K. Kretschmer,et al.  DNA methylation controls Foxp3 gene expression , 2008, European journal of immunology.

[19]  C. Craddock,et al.  Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia. , 2007, Blood.

[20]  M. Labopin,et al.  Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  P. Greenberg,et al.  Activation-induced expression of CD137 permits detection, isolation, and expansion of the full repertoire of CD8+ T cells responding to antigen without requiring knowledge of epitope specificities. , 2007, Blood.

[22]  C. Bokemeyer,et al.  Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation. , 2007, Blood.

[23]  E. Borden,et al.  Overcoming resistance to interferon-induced apoptosis of renal carcinoma and melanoma cells by DNA demethylation. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  T. Gingeras,et al.  CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells , 2006, The Journal of experimental medicine.

[25]  W. Selby,et al.  Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells , 2006, The Journal of experimental medicine.

[26]  M. Maris,et al.  Treatment for Acute Myelogenous Leukemia by Low-Dose, Total-Body, Irradiation-Based Conditioning and Hematopoietic Cell Transplantation From Related and Unrelated Donors , 2006 .

[27]  C. Fathman,et al.  CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation , 2003, Nature Medicine.

[28]  A. Nagler,et al.  Rituximab reduces relapse risk after allogeneic and autologous stem cell transplantation in patients with high‐risk aggressive non‐Hodgkin's lymphoma , 2003, British journal of haematology.

[29]  A. Rudensky,et al.  Foxp3 programs the development and function of CD4+CD25+ regulatory T cells , 2003, Nature Immunology.

[30]  C. Craddock,et al.  Origin and subset distribution of peripheral blood dendritic cells in patients with chronic graft-versus-host disease1 , 2003, Transplantation.

[31]  M. Herlyn,et al.  Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2'-deoxycytidine. , 1994, Cancer research.

[32]  R. Hills,et al.  Independent Prognostic Factors for Aml Outcome Pre-treatment Prognostic Factors , 2022 .